Swiss accept third vaccine against swine flu

The Swiss Agency for Therapeutic Products, Swissmedic, has authorised a third vaccine against swine flu A/H1N1.

This content was published on November 13, 2009 - 17:54

The product is called Celtura and is made by the Swiss pharmaceutical group, Novartis, which is based in Basel.

In a statement on Friday, the federal authorities said that unlike vaccines already authorised in October - Focetria and Pandemrix – the antigen components of Celtura were not based on hens' eggs but on a cell culture.

They said that on the basis of clinical data available, Celtura had been permitted for children above the age of three and for adults of all age groups.

But the data had shown that for adults over the age of 40, sufficient immunisation was only reached after a second vaccination of the drug. This had to be done three weeks after the first.

Swissmedic said it had not received any further applications for the authorisation of vaccines against swine flu. and agencies

Articles in this story

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.